41080 Federal Register / Vol. 72, No.

143 / Thursday, July 26, 2007 / Notices

There are no costs to respondents

except their time to participate in the
survey.

ESTIMATED ANNUALIZED BURDEN HOURS

Average
Number of
Number of burden per Total burden
Respondents Form name responses per
respondents response (in hours)
respondent (in hrs.)

Grantees ........................................... Annual Application ........................... 61 1 25 1525

Annual Report .................................. 61 1 30 1830

Total ........................................... ........................................................... ........................ ........................ ........................ 3355

Dated: July 20, 2007. Name: Advisory Committee for Injury DEPARTMENT OF HEALTH AND
Maryam I. Daneshvar, Prevention and Control. HUMAN SERVICES
Acting Reports Clearance Officer, Centers for Times and Date: 12:30 p.m.–12:55 p.m.,
Disease Control and Prevention. August 20, 2007 (Open). 12:55 p.m.–1:30 Food and Drug Administration
[FR Doc. E7–14439 Filed 7–25–07; 8:45 am] p.m., August 20, 2007 (Closed).
[Docket No. 2007D–0290]
BILLING CODE 4163–18–P
Place: CDC, Koger Center, Vanderbilt
Building, Room 1006, 2939 Flowers Road, Draft Guidance for Industry: Cell
Atlanta, Georgia 30341–3724. Selection Devices for Point of Care
DEPARTMENT OF HEALTH AND Purpose: The committee advises and makes Production of Minimally Manipulated
HUMAN SERVICES recommendations to the Secretary, Autologous Peripheral Blood Stem
Department of Health and Human Services, Cells; Availability
Centers for Disease Control and the Director, CDC, and the Director, NCIPC
Prevention regarding feasible goals for the prevention AGENCY: Food and Drug Administration,
and control of injury. The committee makes HHS.
Advisory Committee for Injury recommendations regarding policies, ACTION: Notice.
Prevention and Control (ACIPC), strategies, objectives, and priorities, and
Science and Program Review reviews progress toward injury prevention SUMMARY: The Food and Drug
Subcommittee and control. Administration (FDA) is announcing the
Matters To Be Discussed: Agenda items for availability of a draft document entitled
In accordance with Section 10(a)(2) of the open portion include the call to order and ‘‘Guidance for Industry: Cell Selection
the Federal Advisory Committee Act introductions and request for public Devices for Point of Care Production of
(Pub. L. 92–463), the Centers for Disease comments. The committee will vote on the Minimally Manipulated Autologous
Control and Prevention (CDC) results of the secondary review. This portion Peripheral Blood Stem Cells (PBSCs)’’
announces, the following meeting for of the meeting will be closed to the public dated July 2007. The draft guidance
the aforementioned committee and in accordance with the provisions set forth in document discusses certain cell
subcommittee: section 552b(c)(4) and (b), title 5 U.S.C., and selection devices that minimally
Name: Science and Program Review the Determination of the Acting Director, manipulate autologous PBSCs at the
Subcommittee (SPRS). Management Analysis and Services Office, point of care for specific clinical
Times and Date: 11:30 a.m.–11:35 a.m., CDC pursuant to Public Law 92–463. indications, and the applicability of the
August 20, 2007 (Open). 11:35 a.m.–12:30 Agenda items are subject to change as requirements to such PBSCs. The
p.m., August 20, 2007 (Closed). priorities dictate. guidance also discusses the submission
Place: CDC, Koger Center, Vanderbilt of data intended to support approval of
For Further Information Contact: Ms. Amy
Building, Room 1006, 2939 Flowers Road,
Atlanta, Georgia 30341–3724. Harris, Executive Secretary, ACIPC, NCIPC, cell selection devices.
Purpose: The subcommittee provides CDC, 4770 Buford Highway, NE., M/S K61, DATES: Although you can comment on
advice on the needs, structure, progress, and Atlanta, Georgia 30341–3724, Telephone any guidance at any time (see 21 CFR
performance of programs in the National (770) 488–4936. 10.115(g)(5)), to ensure that the agency
Center for Injury Prevention and Control The Director, Management Analysis and considers your comment on this draft
(NCIPC). Services Office, has been delegated the guidance before it begins work on the
Matters To Be Discussed: The authority to sign Federal Register notices final version of the guidance submit
subcommittee will have a secondary review, pertaining to announcements of meetings and written or electronic comments on the
discussion, and evaluation on the individual other committee management activities, for
research grant and cooperative agreement
draft guidance by October 24, 2007.
both CDC and the Agency for Toxic ADDRESSES: Submit written requests for
applications submitted in response to the two
Substances and Disease Registry. single copies of the draft guidance to the
Fiscal Year 2007 Requests for Applications
(RFAs) related to the following individual Dated: July 17, 2007. Office of Communication, Training, and
research announcements: RFA–CE–05–020, Elaine L. Baker, Manufacturers Assistance (HFM–40),
Youth Violence Prevention through Center for Biologics Evaluation and
Community-Level Change; and RFA–CE–07– Acting Director, Management Analysis and
Services Office, Centers for Disease Control Research (CBER), Food and Drug
011, Multi-Level Parent Training Administration, 1401 Rockville Pike,
and Prevention.
rwilkins on PROD1PC63 with NOTICES

Effectiveness Trial—Phase II (U49).

Following this meeting, the voting [FR Doc. E7–14430 Filed 7–25–07; 8:45 am] suite 200N, Rockville, MD 20852–1448.
members of ACIPC will meet via Send one self-addressed adhesive label
BILLING CODE 4163–18–P
teleconference to vote on the to assist the office in processing your
recommendations of the SPRS regarding the requests. The draft guidance may also be
RFAs. obtained by mail by calling CBER at 1–

VerDate Aug<31>2005 16:36 Jul 25, 2007 Jkt 211001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\26JYN1.SGM 26JYN1